PerturbMind AI
扰动之心
Shanghai PerturbMind AI Technology Co., Ltd., founded in April 2025 in Jing'an, Shanghai, builds perturbomics-based, geometric world-model-driven AI drug discovery.
Position in SVTR
Snapshot 2026-10-30- Startup SignalsRankedof 2,221new
- Life SciencesRankedof 235new
- AI for ScienceRankedof 111new
- Drug DiscoveryRankedof 64new
- World ModelsRankedof 15
About
Shanghai PerturbMind AI Technology Co., Ltd., founded in April 2025 in Jing'an, Shanghai, builds perturbomics-based, geometric world-model-driven AI drug discovery. Its products include AlphaCell, a virtual-cell state inference world model, and the PerturbSeek ecosystem, targeting disease mechanisms, novel targets and new drug modalities; it has partnered with Roche, AstraZeneca and WuXi AppTec.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-10-29Angel数千万元
Investors · 清松资本, 同杨基金Source · news.pedaily.cn ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- PerturbMind AI
Shanghai PerturbMind AI Technology Co., Ltd., founded in April 2025 in Jing'an, Shanghai, builds perturbomics-based, geometric world-model-driven AI drug discovery. Its products include AlphaCell, a virtual-cell state inference world model, and the PerturbSeek ecosystem, targeting disease mechanisms, novel targets and new drug modalities; it has partnered with Roche, AstraZeneca and WuXi AppTec.
Angel · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- Onyx Bio
Longitudinally tracks population multi-omics data to build a "virtual immune system" model for precision drug development
Seed · 2026-10
— - insitro
ML-driven drug discovery modeling high-throughput cellular data and human clinical/genomic data, with in-house pipeline and pharma partnerships
$400M
$400M - Ten63 Therapeutics
Applies generative AI models to drug discovery and development
$54M · 2026-03
$54M
China
BusinessLatest roundTotal raisedDate- 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base, with an ultra-high-throughput cell perturbation platform to predict drug perturbation effects across cell types, for early-stage drug discovery at pharmaceutical companies and research institutions.
Angel · 2026-10
— - Phil Rivers Technology
Computational medicine and life world models using AI and high-performance computing to simulate disease mechanisms and drug efficacy, systematically discover new oncology targets, assess indications and predict responding patients for novel drug R&D
Series A2 · 2026-08
— - 华源智因
AI virtual cell models for predicting drug efficacy in humans
Seed · 2026-07
—
Europe
BusinessLatest roundTotal raisedDate- Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes
Seed · 2026-10
— - Atlas Bio
In silico clinical trials powered by AI foundation models
Seed · $13M · 2026-10
$13M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - ChemT Biotechnology
CelMo AI virtual cell platform helping biopharma/CDMO companies improve cell culture and antibody production efficiency
Seed · $5M · 2026-06
$5M - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in East China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 4 in East China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 7 in East China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 2 at a nearby stage · 7 in East China
Request intro →HongShan
7 Life Sciences deals in the last 24 months · 5 at a nearby stage · 6 in East China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 4 at a nearby stage · 4 in East China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.